Sarcoma & GIST
From the Sarcoma Foundation of America
From the Journals
The estimated rate of 6-month progression-free survival was 29% overall, though it was 50% in one biomarker-defined patient subset.
Clinical Trial Snapshot
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for...
Chemotherapy, especially with cyclophosphamide and doxorubicin, seems particularly toxic to T cells.
Perivascular epithelioid cell neoplasms (PEComas) are an uncommon class of tumors consisting on histology of perivascular epithelioid cells...
Tumor lysis syndrome in an adolescent with recurrence of abdominal rhabdomyosarcoma: A case report and literature review
IntroductionTumor lysis syndrome (TLS) is a life-threatening oncologic emergency that results when massive cell breakdown occurs either...
Onodera’s Prognostic Nutritional Index in soft tissue sarcoma patients as a predictor of wound complications
Background The ability to predict a wound complication after radiation therapy and surgery for soft tissue sarcomas remains difficult....
Primary cardiac tumors, either benign or malignant, are very rare. The combined incidence is 0.002% on pooled autopsy series.1 The benign tumors...
From the Editor
Introducing The Sarcoma Journal—The Official Journal of the Sarcoma Foundation of America ™ : An Exciting Initiative in Peer-Reviewed Professional Education and Patient Advocacy
The Sarcoma Journal — Official Journal of the Sarcoma Foundation of America™ represents a new and exciting initiative in professional education....
Pulmonary sarcomatoid carcinoma presenting as a necrotizing cavitary lung lesion: diagnostic dilemma
Pulmonary sarcomatoid carcinoma (PSC) is a rare histological subtype that has an aggressive course with average survival of 11-13 months.1 In...